cant. HighBAI/highBDI was significantly different than the other groups (p < 0.01). This pattern was similar for social function, role emotion, mental health. Physical-related SF-36 domains were generally not different between groups. The difference in work-performance scale scores followed the same general pattern of less impairment with lowBAI/lowBDI (for example, WPAIPercent Impairment While Working scale 0.22 + 0.3) and highBAI/highBDI (WPAI Percent Impairment While Working 0.77 + 0.2), p < 0.01. Other work scales followed a similar pattern. BDI routinely was more significant in regression models compared to BAI. CONCLUSION: Comorbid anxiety and depression greatly impair patients. Clinicians and researchers should measure the presence and severity of both mental illnesses when assessing their influence on health-related quality of life and work-performance. While the clinical efficacy of drugs for ADHD is widely studied in clinical trials (usually randomised controlled trials, RCTs), patient preferences with regard to their treatments are not well understood and therefore considered to a less extent. Aim of this study therefore was to explore the patients' perceptions of an "ideal treatment" for ADHD. METHODS: Examination of the state of the art as reported in the literature was followed by a qualitative study with four focus groups consisting of 6-8 parents of ADHD-patients each. In a subsequent quantitative study phase, data was collected in an online or paper-pencil self-fill-in questionnaire for parents of patients and patient (age >14 years) themselves. It included sociodemographic data, treatment history and actual treatment and patients' preferences of therapy characteristics using direct measurement (23 items on a 5-point Likert-scale) as well as a discrete-choice-experiment (DCE, 8 pairs with 6 characteristics). RESULTS: N = 213 questionnaires were filled; most of them by the parents of patients (79% by the mothers, 9% by the fathers). Most of the patients were male (83%) and most of them (83%) had actual medical treatment of ADHD. Direct measurement showed "good emotional quality of live", "no addiction on medication", "improvement of concentration capability," and "few side effects" in the first places. In the DCE, alternatives with "better social quality of life (friendships etc. possible)", "better emotional quality of life (disease not all of the time mentally present)", and "longer duration of medication effect" were more likely to be chosen, giving thus similar results. CONCLUSION: This unique study demonstrates that it is possible to obtain valid and robust information from patients on what constitutes relevant patient outcomes. Such information should play a critical role in appraisal of treatment alternatives by HTA bodies. Signal detection and, ultimately, regulatory approval depend on high-quality, valid and reliable data. The subjective rating scales utilized in CNS clinical trials may be vulnerable to spurious ratings and intentional or unintentional manipulation of ratings by investigators at screening or baseline visits. The objective of this study was to evaluate the feasibility of utilizing a patient reported outcome as a quality assurance measure for evaluation of the quality of a clinician rated primary efficacy measure in a CNS clinical trial. METHODS: A proprietary ratings surveillance system was utilized in a multi-center, double blind, randomized, placebo-controlled clinical trial in which the Hamilton Anxiety Rating Scale (HARS) was the primary efficacy measure. The patient rated Beck Anxiety Inventory (BAI) was added to the baseline visit for quality assurance purposes. Based on published guidelines of the expected relationship between HARS and BAI scores, a computer program flagged aberrant ratings and three flags with the same rater triggered a teaching intervention. The ratings surveillance system was intended both to detect aberrant rating patterns and to deter intentional inflation of ratings in order to qualify subjects.
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RESULTS:
The clinical trial is ongoing. 91 pairs of HARS and BAI ratings have been examined from the randomization visit. 61/91 (67%) pairs were flagged for discordance, in most cases (79%) due to disproportionately high HARS scores compared to the BAI. In 8 cases, the BAI was under 10 with the HARS 22 or greater. In 11 cases, there were at least 3 flags for the same rater and the pattern of discordance was considered to be of sufficient clinical significance to warrant a teaching intervention. CONCLUSION: Use of A128 Abstracts
